1. Experiments were conducted with intact rat hepatocytes to identify inhibitors and incubation conditions that cause selective inhibition of alanine aminotransferase or aspartate aminotransferase. Satisfactory results were obtained by preincubating cells with L-cycloserine or L-2-amino-4-methoxy-trans-but-3-enoic acid in the absence of added substrates. 2. When cells were incubated for 20min with 50 PM-L-cycloserine, alanine aminotransferase activity was decreased by 90%, whereas aspartate aminotransferase was inhibited by 10% or less. On subsequent incubation, synthesis of glucose and urea from alanine was strongly inhibited, but glucose synthesis from lactate was unaffected. 3. L-2-Amino-4-methoxy-trans-but-3-enoic acid (400pUM) in hepatocyte incubations caused 90-95% inactivation of aspartate aminotransferase, but only 15-30% loss of alanine aminotransferase activity. After preincubation with the inhibitor, glucose synthesis from lactate was almost completely blocked; with alanine as the substrate, gluconeogenesis was unaffected, and urea synthesis was only slightly decreased. 4. By comparison with preincubation with inhibitors, simultaneous addition of substrates (alanine; lactate plus lysine) and inhibitors (cycloserine; aminomethoxybutenoic acid) resulted in smaller decreases in aminotransferase activities and in metabolic rates. 5. Other compounds were less satisfactory as selective inhibitors. Ethylhydrazinoacetate inactivated the two aminotransferases to sifhilar extents. Vinylglycine was almost equally effective in blocking the two enzymes in vitro, but was a very weak inhibitor when used with intact cells. Concentrations of DL-propargylglycine (4mM) required to cause at least 90% inhibition of alanine aminotransferase in hepatocytes also caused a 16% decrease in aspartate aminotransferase. 6. When tested in vitro, alanine aminotransferase was, as previously reported by others, more sensitive to inhibition by amino-oxyacetate than was aspartate aminotransferase, but in liver cell incubations the latter enzyme was more rapidly inactivated by amino-oxyacetate.
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This study was undertaken to identify inhibitors and incubation conditions that will cause selective inactivation of AlaAT or AspAT in isolated rat hepatocytes. These two enzymes have important roles in hepatic nitrogen metabolism and gluconeogenesis, and many experiments aimed at elucidating those roles have been conducted with aminotransferase inhibitors that are structurally related Abbreviations used: AlaAT, alanine aminotransferase (EC 2.6.1.2); AspAT, aspartate aminotransferase (EC 2.6.1.1); AMB, L-2-amino-4-methoxy-trans-but-3-enoic acid.
to the amino acid substrates. However, it is often not recognized that such inhibitors may react with a variety of pyridoxal phosphate-dependent enzymes. For example, in addition to several aminotransferases (listed by John et al., 1978) , aminooxyacetate has been reported to inhibit glutamate decarboxylase and histidine decarboxylase (Roberts & Simonsen, 1963; Leinweber, 1968) , alanine racemase (Free et al., 1967) and cystathionase (EC 4.4.1.1; Beeler & Churchich, 1976) . Similarly, Lcycloserine has been shown to inhibit six different aminotransferases (Azarkh et al., 1960; Wong et Vol. 220 al., 1973) . For metabolic studies with intact cells or more complex systems, such broad reactivity raises the possibility that observed effects might be due to actions other than that for which an inhibitor's use was intended.
In spite of reacting with multiple enzymes, it is likely that the concentration of an aminotransferase inhibitor causing inactivation of any one enzyme will be different from those required for inactivation of other catalysts. Therefore we sought to achieve selective inhibition of AlaAT and AspAT by identifying the inhibitor that acts most strongly against each enzyme and by testing for the lowest concentration that causes inactivation with minimal effect on the other enzyme. This paper describes results with six aminotransferase inhibitors and shows that with two of those, Lcycloserine and AMB, selective inactivation of AlaAT and AspAT can be obtained in metabolic experiments with hepatocytes. Since the problem of multiple sites of action is not limited to aminotransferase inhibitors, the approach described may be useful with other classes of metabolic inhibitors. A preliminary account of this work has been presented (Kerich et al., 1983) .
Experimental
Hepatocytes were isolated as described previously (Cornell et al., 1973; Krebs et al., 1974) from 2-day-starved male Wistar rats weighing 200-250g. ATP content in each preparation was measured as an index of cell quality and in all cases was 2.4-2.64umol/g wet wt. of cells.
Hepatocyte incubations with 0.095-0.120g wet wt. of cells in 4ml were conducted at 38°C as described by Cornell et al. (1973) , and, for metabolite measurements, acid extracts were made as described by Crow et al. (1978) . When enzyme activities were to be determined, hepatocytes were rapidly separated from the incubation medium with the use of brominated hydrocarbons and the centrifuge tubes described in detail elsewhere (Cornell, 1980) . The cell pellet was resuspended in Triton X-100 extraction medium (Janski & Cornell, 1980 ), 1 ml/SOmg wet wt. of cells, and kept on ice for 90min with three vortex-mixings during that period. This extraction releases the total cellular content of cytosolic and mitochondrial matrix enzymes. Hepatocyte wet weights were obtained from the measured dry weights and the conversion factor of 3.7 Cycloserine is a structural analogue of alanine, and previous studies with rat liver extracts (Azarkh et al., 1960; Barbieri et al., 1960) or isolated mitochondria (Dieterle et al., 1978) have indicated that AlaAT is more sensitive than AspAT to inhibition by L-cycloserine. However, when used at concentrations of 1-5 mm, as is common in metabolic studies (Parrilla et al., 1974; Meijer et al., 1975 Meijer et al., , 1978 , L-cycloserine will inhibit both AlaAT and AspAT (see below), as well as several other transaminases (Wong et al., 1973; Crabb & Harris, 1978; Tischler et al., 1982) . With isolated rat hepatocytes incubated in the absence of substrates we have found ( Fig. la) that 25 /M-Lcycloserine caused about a 90% decrease in the cellular AlaAT activity in 10min, whereas AspAT was inhibited by only about 5% after 30min. However, as shown by the data in Table 1 , inhibition of AspAT was proportional to the concentration of the inhibitor and reached 70% at 500 pM-L-cycloserine (see also Janski & Cornell, 1981) . AMB AMB is an irreversible inactivator thought to be relatively specific for AspAT (Rando et al., 1976) , and that property has led to recommendations for the use of this aminotransferase inhibitor in metabolic studies (Smith et al., 1977; Smith & Freedland, 1981) . The time course of action of 250 pM-AMB in hepatocyte incubations is shown in Fig. 1 Metabolic effects of cycloserine and AMB With preincubation. The results presented in Fig.  1 and Table 1 show that it is possible selectively to inactivate AlaAT and AspAT in the absence of substrates. This should lead to selective effects on metabolic pathways that involve either or both of those two enzymes. To test this expectation, we conducted hepatocyte incubations with lactate or alanine as the added substrate and measured rates of glucose and urea synthesis. When lactate is the substrate for gluconeogenesis, its oxidation to pyruvate also yields the required NADH, and, in rat liver, the cytosolic oxaloacetate arises via sequential reactions of mitochondrial and cytosolic aspartate aminotransferases; in contrast, glucose synthesis from alanine does not involve AspAT, since pyruvate is generated via AlaAT, and, after carboxylation in the mitochondria, the carbon exits to the cytosol as malate, which is then oxidized to yield oxaloacetate as well as the required NADH (Borst, 1963; Lardy et al., 1965; Haynes, 1965; Walter et al., 1966) . For the experiments described in Table 2 , cells were incubated for 20min without or with an inhibitor before the addition of alanine or lactate. Lysine, which is not glucogenic, was included in the incubations with lactate to accelerate recovery of malate-aspartateshuttle intermediates and to eliminate any lag in the rate of gluconeogenesis .
In hepatocytes preincubated with 25 sM-or 50 pM-L-cycloserine and then incubated with alanine or lactate plus lysine, AlaAT activity was decreased by about 90%, whereas AspAT was decreased by 10% or less. Glucose synthesis from lactate was unaffected, but, when alanine was the added substrate, glucose production was inhibited almost to the rate observed with no added substrate. Likewise, urea synthesis in incubations with alanine and cycloserine was decreased by about 70%, as were alanine utilization and glutamate accumulation, and the amount of aspartate was lowered by 85-90%. These metabolic effects of L-cycloserine are consistent with its selective action on AlaAT when used at low concentrations. Data in AlaAT activity, alanine accumulation was 80% less than in the absence of inhibitor. This observation is explained by results from other experiments showing that preincubation of hepatocytes with 250 pM-or 400 Mm-AMB, by inactivating AspAT, greatly diminishes the capacity for reoxidation of excess cytosolic NADH, and the cumulative conversion of lactate into pyruvate, the substrate for alanine production via AlaAT, is blocked. It should be noted that cessation of glucose synthesis in these experiments occurred with a residual AspAT activity of 39 units/g wet wt. of cells (measured under optimal conditions with hepatocyte extracts). That activity is 15 times the rate of incorporation of lactate into glucose measured in the absence of AMB, and it suggests that a very large excess of cellular AspAT activity is needed for the normal synthesis of glucose from lactate.
Without preincubation. When substrates and (Table 3) , the results were qualitatively similar to those obtained by preincubating the cells with inhibitors (Table  2) . However, the inactivation of enzymes, decreases in urea or glucose synthesis, changes in accumulation of alanine, aspartate and glutamate, and the decline in utilization of added alanine, were all smaller when there was no preincubation with cycloserine or AMB. The differences between the results in Tables 3 and 2 are greater for the experiments with AMB than for those with cycloserine, and that contrast reflects the different rates with which these agents inactivate AlaAT or AspAT (Fig. 1) . In this regard, it was unexpected that the inactivation of AspAT by AMB would be less with alanine than with lactate plus lysine As added substrate. For example, with 250 pM-AMB, in the lactate-containing incubations AspAT was decreased by 75%, whereas in the presence of alanine the decrease was only 53% (Table 3) . The same trend occurred with 400 M-AMB and was also apparent, but less pronounced, when cells were preincubated with the inhibitor (Table 2) .
Amino-oxyacetate
Amino-oxyacetate is perhaps the most widely used of all aminotransferase inhibitors. In spite of increasing evidence that it is a general reagent reacting with the pyridoxal moiety of many aminotransferases and other enzymes (see the introduction), we tested amino-oxyacetate for its selectivity against hepatocyte AlaAT and AspAT. As seen from the results in Table 4 , 50 pM-aminooxyacetate in the absence of added substrates caused 93% inhibition of AspAT within 10min, but, concomitantly, AlaAT was inhibited by 43% at 0min and by 61% at 30min. The same lack of selectivity was observed with lower concentrations of amino-oxyacetate. That is, in 1Omin incubations with 25 pM-amino-oxyacetate, hepatocyte (Harris et al., 1982) . We have found, however, that amino-oxypropionate causes similar inhibition of AspAT and AlaAT and has the same low selectivity as those described above for aminooxyacetate (results not shown).
With regard to the values given here for the inhibition of aminotransferases by amino-oxyacetate, it should be noted that, when hepatocytes are incubated with this inhibitor and enzymes are extracted and assayed in vitro, aminotransferases show a slow re-activation on addition of the amino acid substrate. This has been described in detail for AspAT , and it also applies to AlaAT. For example, with extracts of cells incubated with 50,uM-amino-oxyacetate, AlaAT activity was inhibited by 47% when calculated from the reaction in the first 4min after addition of alanine; if the calculation is based on the rate in the 4-8 min interval after initiating the reaction with alanine, the apparent inhibition falls to 38%. In the present work, all values for inhibition by aminooxyacetate are calculated for the first 4min interval after the assay reactions were begun with aspartate for AspAT or alanine for AlaAT.
Although it was expected that amino-oxyacetate would inhibit both aminotransferases examined in this study, it was surprising that, in hepatocyte incubations, AspAT was more rapidly and more strongly inhibited than AlaAT. With rat liver extracts prepared by standard homogenization techniques, both Hopper & Segal (1964) and Rofe & Edwards (1978) have reported that AlaAT is much more sensitive to inhibition by aminooxyacetate than is AspAT. We observed the same order of sensitivity (Table 5) with hepatocyte extracts prepared as described in the Experimental section. Thus, when amino-oxyacetate is used with intact cells, its relative reactivity towards AlaAT and AspAT is reversed from that seen when this inhibitor is used in vitro. It is possible that AlaAT is, as in vitro, more strongly affected in cells, but is re-activated by cell disruption and extraction to a greater extent than is amino-oxyacetate-inhibited AspAT.
Propargylglycine Marcotte & Walsh (1975) reported that AlaAT in vitro was 50% inactivated in about 5min by lOmM-DL-propargylglycine, but no loss of AspAT activity occurred during a 10min treatment with 100mM-propargylglycine. Subsequently (Tanase & Morino, 1976) it was found that purified pig heart AspAT was very slowly inactivated when the enzyme was incubated with pyruvate or 2-oxoglutarate as well as 100 mM-L-propargylglycine; the times for half-inactivation in the presence of pyruvate were 2-4h, but were much decreased when the incubations were conducted in 3M-potassium formate. These observations in vitro suggested that propargylglycine might be useful as a selective inactivator of AlaAT in whole cells. Results of tests with isolated hepatocytes (Table 6) show that 4mM-DL-propargylglycine is required to achieve 90% inactivation of AlaAT in 20min. It is likely that the L-isomer is the active component of the racemic propargylglycine used here, but, on that assumption, the concentration of propargylglycine required for 90% inactivation of rat liver AlaAT would still be at least 40 times the concentration of L-cycloserine required to achieve that effect (cf. Table 6 with Table 1 and Fig. 1 ). In contrast with our expectation based on the enzyme studies in vitro, hepatocyte AspAT was partially Table 5 . Inhibition of AlaA T or AspA T in vitro with or without preincubation with amino-oxyacetate Hepatocytes were, extracted as described in the Experimental section for release of total cellular enzyme activities.
Samples of the cell extracts were added to enzyme assay' buffer at 3SC, followed by amino-oxyacetate at the indicated concentrations. In some instances, ('-preincubation'), reaction was initiated immediately; in others ('+preincubation'), reaction was initiated after 15min at 38°C. Inhibitions were calculated relative to assays without amino-oxyacetate but run in parallel with those containing the inhibitor. Results are from a representative set of assays with an extract containing 439 and 29.3 units/g wet wt. of AspAT and AlaAT respectively. inactivated by propargylglycine, and the concentration causing a 90% decrease in AlaAT also lowered AspAT activity by 16% (Table 6 ). Thus, compared with cycloserine, propargylglycine is slightly less selective, as well as requiring much higher concentrations for its actions against aminotransferases in intact cells.
Vinylglycine
Vinylglycine (2-aminobut-3-enoic acid), the parent compound for AMB, is an irreversible inactivator of pig heart AspAT in vitro (Rando, 1974a ), but it is described as having no effect on AlaAT (Marcotte & Walsh, 1976 ). However, when tested with extracts of rat hepatocytes, DL-vinylglycine inhibited both aminotransferases, and the inhibition of AlaAT was slightly greater than that of AspAT. It is not known whether this discrepancy is due to species differences, to differences in states of enzyme purity or to some other cause. We also tested vinylglycine in incubations of intact hepatocytes and found its action to be weaker than with cell extracts. That is, 4mM-DL-vinylglycine caused 57% and 69% inhibition, respectively, of AspAT and AlaAT in vitro (Table 7) , but, in 30min incubations of three cell preparations with 4mM-DL-vinylglycine, the observed percentage decreases (means+S.E.M.) were only 22.4+1.9 for AlaAT and 5.7+0.9 for AspAT. Thus, both in hepatocytes and in vitro, vinylglycine was more active against AlaAT. This compound, however, is the weakest aminotransferase inhibitor of any that we have tested with rat hepatocytes, and it seems unlikely that vinylglycine would be useful as an aminotransferase inhibitor in studies of cellular metabolism.
Ethyl hydrazinoacetate
The use of ethyl hydrazinoacetate in metabolic experiments was first reported by Rognstad (1980) , who found that this inhibitor acted with many of the characteristics of amino-oxyacetate. That is, acetate, as with amino-oxyacetate, it appears that inhibition of AspAT, which is adequate for metabolic studies, would be accompanied by a large inhibition of AlaAT.
Discussion
In this paper we have described aminotransferase inhibitors in terms of their selective action against AlaAT and AspAT. Generally inhibitors are discussed in terms of their specificity, but the description of an inhibitor as specific often is taken to mean that it acts at a unique site or with one class of enzymes. We have chosen to refer to selectivity in order to emphasize the probability than all metabolic inhibitors, when used with intact cells or more complex systems, will have multiple sites of action. For example, pyrazole and its 4-substituted derivatives are well-known inhibitors of alcohol dehydrogenase, and occasionally they are spoken of as being specific for that action (see, e.g., Blomstrand et al., 1979) . However, 4-hydroxypyrazole, a liver metabolite of pyrazole, has been shown to be a potent inactivator of catalase in vivo (MacDonald & Pispa, 1980) and in isolated hepatocytes (Harris et al., 1982) . Furthermore, each of the inhibitors used in the present study acts against enzymes other than aminotransferases. Of those, AMB, which probably has the fewest reported additional sites of action, has been shown to be a substrate for deamination by threonine dehydratase (Kapke & Davis, 1975) , to cause inactivation of tryptophan synthase (Miles, 1978) , to antagonize methionine uptake and utilization and inhibit the growth of cultured tumour cells (Tisdale, 1980) , and to inhibit enzymes of S-adenosylmethionine synthesis (Sufrin et al., 1982) .
Because of the problems outlined above, six aminotransferase inhibitors were tested in hepatocyte incubations to determine which inhibitors are capable of causing at least a 90% decrease in either AlaAT or AspAT activity with an acceptably small effect on the other and to determine the lowest concentrations required to achieve that degree of selective inhibition. For AlaAT, 90% inhibition was obtained with 50uM-L-cycloserine or 4mM-DLpropargylglycine, and the concomitant decreases in AspAT were about 10% for cycloserine and 16% for propargylglycine (Tables 1 and 6 ). The difference in effects of these two inhibitors on AspAT is probably of no metabolic significance, since isolated rat hepatocytes contain 400-500 units of AspAT/g wet wt., and a decrease as large as 16%
would still leave a cellular activity of more than 300units/g. However, the high concentration of propargylglycine required for inactivation of AlaAT might increase the possibility of spurious effects due either to actions on other classes of enzymes or to metabolism of the inhibitor itself. The latter is known to be a problem with millimolar concentrations of amino-oxyacetate (Harris et al., 1982) . Thus L-cycloserine seems to be the best material for selective inactivation of AlaAT. For AspAT, selective inactivation can be achieved with AMB, although more slowly than with cycloserine acting on AlaAT (Fig. 1) . Inactivation of AspAT was accelerated by increasing the concentration of AMB from 250Mm to 1 mM, but that was accompanied by greater inactivation of AlaAT (see Table 1 and the text). Therefore, for metabolic experiments, it was decided to keep the inhibitor concentration below 500 /M and to preincubate for 20min to allow for inactivation of AspAT.
When hepatocytes were preincubated with AMB or cycloserine (Table 2) , we observed large metabolic effects indicative of selective inactivation of AlaAT or AspAT. However, all of those effects were diminished when the inhibitors and substrates were added simultaneously (Table 3) . Although AlaAT was decreased by cycloserine, other measurements show that this occurred largely during the second half of the 30min incubation period; that is, the time course for AlaAT shown in Fig. 1 was displaced to the right. In agreement with that observation, with no preincubation alanine utilization was not inhibited by 25fM-L-cycloserine, and the decrease caused by 50Mm (28%) was less than half of the inhibition (67%) when cells were preincubated with 50uM-cycloserine (Tables 2 and 3 ). It was previously reported (Janski & Cornell, 1981) that the inactivation of hepatocyte AspAT caused by 1 mM-Lcycloserine was greatly diminished when the inhibitor and a lactate/oleate/NH4Cl substrate mixture were simultaneously added to incubations. Likewise, with AMB, aspartate has been shown to prevent the inactivation of AspAT in vitro (Rando, 1974b) , and, in hepatocyte experiments, preincubation with AMB was required for full inactivation of AspAT when the incubations also included ornithine, NH4Cl and either lactate or pyruvate (Smith & Freedland, 1981) . It was unexpected, however, that, as seen in Table 3 and also evident  in Table 2 
